Allegria Therapeutics has secured USD 5.1 million in a seed extension financing round led by ALK-Abelló, with additional participation from HighLight Capital, the Lichtsteiner Foundation, and existing backer Forty51 Ventures. The Swiss biotechnology company will use the funds to nominate its first clinical candidate and advance its portfolio of mast cell-modulating therapies for allergy and […]
Sōlaria Biō has disclosed new mechanistic data showing that its synbiotic medical food, Bondia, reinforces gut barrier integrity, reduces systemic inflammation, and suppresses osteoclast activity—offering biological insight into the 85 percent improvement in bone density reported in a prior large-scale clinical trial. These results support Bondia’s positioning as a novel intervention for osteopenia and age-related […]
Pillar Biosciences has expanded its collaboration with AstraZeneca to bring its next-generation sequencing-based liquid biopsy kits to China, aiming to accelerate localized tumor profiling and broaden access to precision oncology diagnostics. The partnership, which includes Shanghai Zhengu Biological Technology Co., Ltd., is designed to support assay implementation across Chinese hospital laboratories to reduce diagnostic turnaround […]
Anixa Biosciences Inc. has reported final Phase 1 results for its investigational breast cancer vaccine targeting the α-lactalbumin protein, showing that the primary endpoints were met and 74 percent of participants demonstrated protocol-defined immune responses. The data were presented at the 2025 San Antonio Breast Cancer Symposium and build the case for a Phase 2 […]
Innovent Biologics has reported that mazdutide, its dual GLP-1 and glucagon receptor agonist, achieved statistically significant reductions in both body mass index and weight in Chinese adolescents with obesity during a 12-week Phase 1b clinical trial. The trial met its primary endpoint, demonstrated a favorable safety profile, and paves the way for a Phase 3 […]
STADA Arzneimittel AG and Bio-Thera Solutions have secured a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for Gotenfia, a proposed biosimilar to the tumor necrosis factor alpha inhibitor golimumab. The product references Simponi, an originator drug widely prescribed for multiple autoimmune conditions. If approved, Gotenfia would be marketed […]
Insilico Medicine has licensed its AI-discovered oral PHD inhibitor ISM4808 to TaiGen Biotechnology for exclusive development and commercialization in the Greater China region, including Mainland China, Hong Kong, Macau, and Taiwan. The deal follows Investigational New Drug clearance in China in 2023 and positions TaiGen to bring the asset into clinical trials targeting anemia associated […]
Swedish Orphan Biovitrum AB has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for Aspaveli, the pegcetacoplan-based therapy developed in partnership with Apellis Pharmaceuticals Inc., for the treatment of C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. The recommendation covers use in patients aged 12 years and older […]
Roivios Ltd., a clinical-stage medical device developer, has announced encouraging results from its first-in-human study of the JuxtaFlow Renal Assist Device, a technology designed to support fluid removal and renal function in patients with diuretic-resistant cardiorenal syndrome and acute decompensated heart failure. The results, published in the ASAIO Journal, showed that JuxtaFlow significantly improved both […]
AusperBio Therapeutics, Inc. announced that its lead investigational product, AHB-137, achieved a 30% functional cure rate as a 24-week monotherapy in HBeAg-negative chronic hepatitis B patients already on stable nucleos(t)ide analogue therapy. The data, presented at HEP-DART 2025, showed that patients with baseline HBsAg 100–1,000 IU/mL reached this endpoint at Week 72 in the company’s […]